Abbott Laboratories (ABT)vsStandard Biotools Inc (LAB)
ABT
Abbott Laboratories
$110.92
+1.08%
HEALTHCARE · Cap: $182.49B
LAB
Standard Biotools Inc
$0.79
+0.84%
HEALTHCARE · Cap: $314.06M
Smart Verdict
WallStSmart Research — data-driven comparison
Abbott Laboratories generates 54967% more annual revenue ($46.59B vs $84.60M). LAB leads profitability with a 100.4% profit margin vs 11.7%. ABT earns a higher WallStSmart Score of 52/100 (C-).
ABT
Buy52
out of 100
Grade: C-
LAB
Hold43
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-46.9%
Fair Value
$73.92
Current Price
$110.92
$37.00 premium
Margin of Safety
+89.8%
Fair Value
$11.65
Current Price
$0.79
$10.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Generating 2.1B in free cash flow
Reasonable price relative to book value
Keeps 100 of every $100 in revenue as profit
Conservative balance sheet, low leverage
Areas to Watch
Expensive relative to growth rate
Premium valuation, high expectations priced in
Earnings declined 47.5%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -16.8% — below average capital efficiency
Revenue declined 7.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABT
The strongest argument for ABT centers on Market Cap, Free Cash Flow. Revenue growth of 13.0% demonstrates continued momentum.
Bull Case : LAB
The strongest argument for LAB centers on Price/Book, Profit Margin, Debt/Equity. Profitability is solid with margins at 100.4% and operating margin at -38.9%.
Bear Case : ABT
The primary concerns for ABT are PEG Ratio, P/E Ratio, EPS Growth.
Bear Case : LAB
The primary concerns for LAB are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ABT profiles as a value stock while LAB is a declining play — different risk/reward profiles.
LAB carries more volatility with a beta of 1.40 — expect wider price swings.
ABT is growing revenue faster at 13.0% — sustainability is the question.
ABT generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
ABT scores higher overall (52/100 vs 43/100) and 13.0% revenue growth. LAB offers better value entry with a 89.8% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abbott Laboratories
HEALTHCARE · MEDICAL DEVICES · USA
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Visit Website →Standard Biotools Inc
HEALTHCARE · MEDICAL DEVICES · USA
Standard Biotools Inc. (LAB) is a pioneering biotechnology company dedicated to enhancing genomic analysis and biological research through cutting-edge tools and technologies. The firm's focus on developing high-performance products for laboratories in genomics and proteomics is aimed at improving research precision and operational efficiency. Utilizing proprietary platforms, Standard Biotools accelerates scientific discoveries, reinforcing its position as a leader in the dynamic biotechnology landscape. With a commitment to meeting the growing demand for innovative analytical solutions, LAB is strategically positioned to facilitate significant advancements within the life sciences sector.
Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?